Phio Pharmaceuticals (PHIO) Operating Expenses (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Operating Expenses came in at $4.2 million in Q1 2026, up 122.6% YoY from $1.9 million in Q1 2025, and up 66.35% on a QoQ basis from $2.5 million in Q3 2025.
Phio Pharmaceuticals (PHIO) Operating Expenses (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Operating Expenses data on file, last reported at $4.2 million in Q1 2026.
- Quarterly Operating Expenses rose 122.6% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (up 27.39% YoY) and the FY2024 annual result came in at $7.4 million, down 31.75% from the prior year.
- Operating Expenses climbed to $4.2 million in Q1 2026, from $2.5 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $4.2 million in Q1 2026 to a low of $1.6 million in Q3 2024.
- A 5-year average of $2.5 million and a median of $2.5 million in 2022 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2024 — Operating Expenses plunged 42.72% — and 2026, when it jumped 122.6%.
- Tracing PHIO's Operating Expenses over 5 years: stood at $2.7 million in 2022, then tumbled by 30.44% to $1.9 million in 2023, then declined by 11.85% to $1.7 million in 2024, then surged by 49.64% to $2.5 million in 2025, then surged by 66.35% to $4.2 million in 2026.
- The last three Operating Expenses figures came in at $4.2 million (Q1 2026), $2.5 million (Q3 2025), and $2.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | 4.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.27 Mn |
| Mar 31, 2026 | 4.17 Mn |
| Sep 30, 2025 | 2.51 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Mar 31, 2025 | 1.87 Mn |
| Dec 31, 2024 | 1.67 Mn |
| Sep 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 1.91 Mn |
| Mar 31, 2024 | 2.21 Mn |
| Dec 31, 2023 | 1.90 Mn |
| Sep 30, 2023 | 2.78 Mn |
| Jun 30, 2023 | 2.55 Mn |
| Mar 31, 2023 | 3.60 Mn |
| Dec 31, 2022 | 2.73 Mn |
| Sep 30, 2022 | 3.57 Mn |
| Jun 30, 2022 | 2.52 Mn |
| Mar 31, 2022 | 2.64 Mn |
| Dec 31, 2021 | 3.45 Mn |
| Sep 30, 2021 | 3.74 Mn |
| Jun 30, 2021 | 2.68 Mn |